Vontac may be used for:
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Vontac is a potassium-competitive acid blocker (P-CAB) used to reduce stomach acid production. It is indicated for the treatment of gastric and duodenal ulcers, reflux esophagitis, and for preventing ulcer recurrence in patients taking low-dose aspirin or NSAIDs. It may also be used as part of combination therapy to eradicate Helicobacter pylori (H. pylori).
There is limited clinical experience with vonoprazan overdose. If an overdose occurs, treatment is primarily symptomatic and supportive.
Vonoprazan is not effectively removed from the bloodstream through hemodialysis. A suspected overdose should be assessed promptly by a healthcare professional.
Vonoprazan is a potassium-competitive acid blocker (P-CAB). It reversibly and competitively inhibits the H⁺/K⁺-ATPase proton pump in gastric parietal cells.
By blocking this final step in stomach acid production, Vontac strongly and persistently reduces gastric acid secretion. This helps relieve acid-related symptoms and supports healing and prevention of damage to the upper gastrointestinal tract.
Children:
The safety and effectiveness of vonoprazan have not been adequately established in patients below 18 years of age. Use in children and adolescents is therefore not generally recommended.
Elderly:
Older patients may have reduced kidney or liver function and should be monitored carefully during treatment.
Kidney impairment:
No dose adjustment is generally required for mild to moderate renal impairment (eGFR 30–89 mL/min). Use should be avoided in severe renal impairment (eGFR below 30 mL/min) unless specifically directed by a specialist.
Liver impairment:
No adjustment is generally required in mild hepatic impairment. Vonoprazan should be avoided in patients with moderate to severe hepatic impairment unless specifically recommended by a healthcare professional.
Vontac may be taken with or without food.
Gastric ulcer:
20 mg once daily for 8 weeks.
Duodenal ulcer:
20 mg once daily for 6 weeks.
Reflux esophagitis:
20 mg once daily for 4 weeks. If healing is inadequate, treatment may be extended, but generally not beyond 8 weeks.
Maintenance treatment for recurrent reflux esophagitis:
10 mg once daily. If the response is inadequate, the dose may be increased to 20 mg once daily.
Prevention of ulcer recurrence with low-dose aspirin:
10 mg once daily.
Prevention of ulcer recurrence with NSAIDs:
10 mg once daily.
When used as part of H. pylori eradication treatment, the following regimen may be prescribed for 7 days:
First-line triple therapy:
In certain circumstances, the clarithromycin dose may be increased by the physician, but it should not exceed the recommended maximum.
Alternative therapy when previous PPI-based triple therapy has failed:
These antibiotic combinations should only be taken under medical supervision.
Vonoprazan should be used during pregnancy only when the expected benefits clearly outweigh the potential risks.
There is limited information regarding its use during breastfeeding. If treatment is considered essential, the doctor may recommend discontinuing breastfeeding during therapy.
⚠️Disclaimer:
At ePharma, we’re committed to providing accurate and accessible health information. However, all content is intended for informational purposes only and should not replace medical advice from a qualified physician. Please consult your healthcare provider for personalized guidance. We aim to support, not substitute, the doctor-patient relationship.